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Abstract
Toll-like receptor 2-agonistic lipopeptides typified by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-
cysteinyl-S-serine (PAM2CS) compounds are potential vaccine adjuvants. In continuation of
previously reported structure-activity relationships on this chemotype, we have determined that at
least one acyl group of optimal length (C16) and an appropriately orientated ester carbonyl group
is essential for TLR2-agonistic activity. The spacing between one of the palmitoyl ester carbonyl
and the thioether is crucial to allow for an important H-bond, which observed in the crystal
structure of the lipopeptide:TLR2 complex; consequently, activity is lost in homologated
compounds. Penicillamine-derived analogues are also inactive, likely due to unfavorable steric
interactions with the carbonyl of Ser 12 in TLR2. The thioether in this chemotype can be replaced
with a selenoether. Importantly, the thioglycerol motif can be dispensed with altogether, and can
be replaced with a thioethanol bridge. These results have led to a structurally simpler, synthetically
more accessible, and water-soluble analogue possessing strong TLR2-agonistic activities in human
blood.
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Introduction
The phenotypic and functional characterization of T lymphocytic responses as Th1 and Th2
are based on their profile of cytokine secretion in both CD4+ T helper (Th) and CD8+ T
cytotoxic (Tc) cell subsets. Human Th1 and Th2 lymphocytes not only elaborate distinct sets
of cytokines, but also exhibit distinct functional outcomes.1 Th1 immunity is currently
thought to play a central role in the adaptive immune response against intracellular
pathogens, while Th2 responses are important in containing parasitic infections, especially
intestinal nematodes.2;3 Several factors determine Th polarization and effector functions.4–7
Of particular interest to us is the relationship between the engagement of specific innate
immune receptors in the antigen-presenting cell, notably Toll-like receptors (TLRs), and the
initiation and development of Th1- or Th2-directed immune responses.7–11 We are
interested equally in TLR-agonistic chemotypes that evoke dominant Th1,12;13 Th2,14 or
balanced Th1/Th215;16 immune responses for purposes of evaluating them as vaccine
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adjuvants. We had previously reported a detailed structure-activity relationship on TLR2-
agonistic lipopeptides, typified by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-
serine (PAM2CS) analogues,14 which focused on examining the role of the structurally
indispensable Cys residue, its linkage to the diacylthioglycerol backbone, as well as the
geometry and stereochemistry of the Cys-Ser dipeptide unit. PAM2CS distinguishes itself
from virtually all other TLR agonists in that although the lipopeptide is devoid of any
detectable pro-inflammatory activity in ex vivo human blood models,15 or of local
reactogenicity and pyrogenicity in rabbit models,17 it is potently adjuvantic in murine
models of immunization,15 suggesting that this chemotype may be a safe and effective
adjuvant. Although conflicting reports exist as to its Th1- or Th2-polarizing
propensities,18–21 we have observed a distinct Th2 bias (IgG1 > IgG2a)22;23 relative to
glucopyranosyl lipid A (a more potent TLR4-agonistic analogue24;25 of monophosphoryl
lipid A26;27), and an TLR7-agonistic imidazoquinoline that we had described earlier,12;28 in
our preliminary murine immunization screens with bovine α-lactalbumin as a model subunit
antigen (Fig. 1).
The results obtained illustrate the importance of at least one acyl group of optimal length
(C16) and an appropriate orientation of the ester carbonyl group. The spacing between one of
the palmitoyl ester carbonyl and the thioether is crucial to allow for an important H-bond,
which is observed in the crystal structure of the lipopeptide:TLR2 complex; consequently,
activity is lost in homologated compounds. Penicillamine-derived analogues are also
inactive, likely due to unfavorable steric interactions with the carbonyl of Ser 12 in TLR2.
The thioether in this chemotype can be replaced with a selenoether. The thioglycerol motif
can be dispensed with altogether, and can be replaced with a thioethanol bridge. These SAR
studies have led to the identification of a structurally simpler, synthetically more accessible,
and water-soluble analogue possessing strong TLR2-agonistic activities in human blood.
Results and Discussion
We are specifically interested in examining the adjuvanticity of TLR2-agonistic compounds
using formulations that do not require oil-in-water emulsions such as MF59.29;30 The
overarching goal of the structure-activity relationship studies presented herein was therefore
to derive entirely water-soluble analogues and part-structures of PAM2CS, with a focus on
the fatty-acyl substituent on the diacylthioglycerol backbone. We began with attempts to
examine the consequences of replacing palmitoyl groups with unsaturated fatty acids,
hypothesizing that the phase transition temperatures of such analogues would be
considerably lower, thereby enhancing aqueous solubility. The synthetic strategy that we
had used previously utilized global deprotection of acid-labile protecting groups,14 which
was found to degrade the unsaturated fatty acids, resulting in unacceptably low yields. We
therefore elected to replace the terminal serine with glycine ester, eliminating the necessity
for an additional protecting group, noting that this substitution is tolerated without any
significant loss of activity.31;32 The syntheses of linoleic- [8, cis, cis-9,12-octadecadienoic
acid] and α-linolenic acid (9, all-cis-9,12,15-octadecatrienoic acid) bearing analogues were
carried out (Scheme 1), with (R)-2-(tert-butoxycarbonyl)-3-(((R)-2,2-dimethyl-1,3-
dioxolan-4-yl)methylthio)propanoic acid, 1, as the synthon.14 Methyl or ethyl esters of the
terminal glycine in these analogues resulted in undesired diketopiperazine side products, a
problem that was obviated by using the isopropyl ester. Compounds 8 and 9, as well as the
di-palmitoyl analogue with the isopropyl glycine ester (7), were all found to be highly active
as TLR2 agonists, with mid-picomolar to low nanomolar EC50 values (Table 1) in TLR2-
specific reporter gene assays, which are comparable to that of PAM2CS-OMe, the reference
compound. These analogues were not water-soluble, however.
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Analogues with the α-amino group of cysteine acylated with long-chain fatty acids (such as
PAM3CSK433) are also highly potent, but engage TLR1/2 heterodimers rather than TLR2/6
dimerization induced by the diacyl PAM2CS chemotype.34;35 We asked if substituting the
N-acyl moiety with polar or zwitterionic functional groups could result in modulation of
TLR2 activity. Our attempts at direct S-alklyation of the highly polar glutathione with 4-
(iodomethyl)-2,2-dimethyl-1,3-dioxolane did not proceed smoothly, and we found it simpler
instead to couple the γ-carboxylic acid of L-glutamic acid directly to the free amine of
cysteine (Scheme 1); compound 11, however, was found to be virtually inactive, indicating
that polar appendages at this position are not be tolerated.
We had previously not examined the role of the acyl chain lengths on TLR2-agonistic
activity, and limited SAR studies are available only for the triacyl species.36 Analogues
bearing lauroyl (17, C12), myristoyl (18, C14), and stearoyl (19, C18) were synthesized as
outlined in Scheme 2, but were found to be lower in activity than the parent PAM2CS
compound (Fig. 2, Table 1), indicating that the C16 chain length is optimal. Next, we sought
to explore if replacement of one or both of the acyl chains with polyether or polyamine
substituents will impart water solubility without significantly affecting activity. A terminal
carboxylic acid functional group was installed on commercially-available 3-(2-(2-
ethoxyethoxy)ethoxy) propan-1-amine, 3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propan-1-
amine (mono-Boc protected) or N1, N2, N3-tri-Boc-spermine37;38 by sequential reaction with
methyl 2-bromoacetate, Boc-protection of the resultant secondary amines, and hydrolysis of
the methyl ester (Scheme 3a). The intermediary Boc-protection of the otherwise zwitterionic
compounds facilitated extraction and isolation of the carboxylic acids (22a–c) into organic
layers. Esterification of the 13 proceeded uneventfully only with 22a, affording the
diacylated species 24 (Scheme 3b). Compound 24 was found to be inactive (Table 1). The
other two carboxylates (22b, 22c) yielded mixtures of mono- and di-acylated products, even
with large excesses of reagents and under long reaction times, which proved intractably
difficult to isolate to homogeneity. We therefore attempted palmitoylation of the monoacyl
intermediates and obtained 31–33 in which we presume that the first acylation occurred
predominantly, if not exclusively on the primary hydroxyl group of the glycerol unit.
Compounds 31–33, all of which were highly water-soluble, were found to be surprisingly
active (Fig. 2), which appeared to suggest that a single acyl chain may be sufficient for
TLR2 occupancy and signaling.
We therefore systematically evaluated analogues monoacylated on the primary (35) and
secondary alcohols (38) of the glycerol unit (Scheme 4). Compound 38 with the palmitoyl
group on the secondary alcohol was synthesized by first protecting the primary hydroxyl
group (Scheme 4). Both monoacyl compounds were unexpectedly active in TLR2-specific
reporter gene assays, with EC50 values comparable to that of PAM2CS-OMe (Fig. 2). These
findings raised the possibility that the glycerol derived backbone could perhaps be dispensed
with altogether, and analogues with simpler scaffolds would still retain activity. We
therefore directly S-alkylated the appropriately-protected Cys-Ser synthon 41 with 2- or 3-
iodoalkanol. Acylation of the resulting terminal primary alcohol with palmitoyl chloride,
and global deprotection yielded the desired compounds 44 and 47 with di-, and tri-
methylene spacers between the ester and the thio-ether functionalities, respectively (Scheme
5). Compound 44 was found to be quite active (EC50: 2.75 ng/mL; 4.4 nM) in primary
screens, whilst 47 was completely inactive (Fig. 2). These results strongly indicated that the
intervening segment between the long-chain ester and the thioether was a crucial
determinant of TLR2 activity. In order to test whether the orientation of the carbonyl group
on the palmitoyl ester also played a role, we synthesized 50 and 53 via S-alkylation of the
protected Cys-Ser synthon with 2- or 3-iodoalkanoic acid, esterification with 1-hexadecanol,
and deprotection (Scheme 5). Both compounds were virtually bereft of activity (Fig. 2,
Table 1), verifying that the position and orientation of the ester carbonyl is also critical.
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Analogues with L-cysteine replaced with D- or L-penicillamine (59 and 64, respectively), or L-
homocysteine (69) were all inactive, as was the des-amino analogue 74 (Table 1).
Taken together, these results illustrate clearly the importance of at least one acyl group of
optimal length (C16) and an appropriate orientation of the ester carbonyl group. A two
methylene spacer between the palmitoyl ester and the thioether is essential as is evident
from the activity profiles of 38 and 44, since activity is lost in the homologated analogue
(47). The only apparent exception to this rule would be the observation that 35 with a three-
carbon spacing is also active.
All of these observations, including the above-mentioned exception, as well as the loss of
activity in the homocysteine (69) and penicillamine (59, 64) analogs can be rationalized on
the basis of the crystal structure of PAM2CSK4 bound to the TLR2/TLR6 heterodimer.39;40
The overall binding energetics of PAM2CSK4 appears to be driven by dominant
hydrophobic interactions of the two acyl chains of PAM2CSK4 with nonpolar side-chains of
residues lining a hydrophobic tunnel, with a relative paucity of multiple H-bonds; the
dimensions of this tunnel can easily accommodate a single acyl chain, such as present in
compound 44 (Fig. 4). However, a H-bond between the amide NH of Phe 349 of TLR2 and
the carbonyl oxygen atom of the palmitoyl ester at the secondary hydroxyl of the
thioglycerol backbone appears to be pivotal in orienting the lipopeptide in its binding pocket
(Fig. 4). This interaction would be disfavored either if the spacing between the thioether and
the carbonyl is lengthened (as would be the case in compound 47), or if the orientation of
the carbonyl group of the ester were to be inverted as in compounds 50 and 53. There are
two additional H-bonds stabilizing the complex, both of which involve the cysteine-derived
part of the lipopeptide: The NH2 on the α-carbon of cysteine is H-bonded with the carbonyl
of Phe 317 (not possible in the des-amino analog, 74), and the carbonyl of cysteine is H-
bonded with the NH of Phe 319 (disrupted in the homocysteine analog, 69). It may also be
noted that the dimethyl groups on the β-carbon of the cysteine in the penicillamine
derivatives (59, 64) would be expected to impose unfavorable steric interactions (Fig. 4).
We had earlier demonstrated the importance of the thioether bridge in determining TLR2
activity since oxoether analogues were found to be inactive.14 It was therefore of interest to
examine if selenocysteine could substitute for cysteine. Compound 79 was synthesized by
direct, in situ selenoalkylation (Scheme 7), and was found to be as active as PAM2CS (Table
1).
We elected to examine the activities of 44 (active in primary screens) and the
selenocysteine-derived compound 79 in secondary screens using ex vivo whole human blood
models. We selected appropriate experimental models based on our earlier characterization
of the activity profile of this chemotype, which includes strong and rapid CD11b
upregulation and p38 mitogen-activated kinase (p38MAPK) induction in human neutrophils,
but not the induction of any significant levels of proinflammatory cytokines in human blood
or isolated peripeheral blood mononuclear cells.17
We observed prominent CD11b upregulation and p38MAPK phosphorylation for 44, the
magnitude of which is greater than that of PAM2CS (Fig. 3); the apparent higher potency in
whole human blood may be a consequence of differential plasma protein binding, and the
consequent effects of free (unbound) agonist.17;41 Our continued SAR studies on the TLR2-
agonistic lipopeptide chemotype have led to the identification of a structurally simpler,
synthetically more accessible, and water-soluble analogue possessing strong TLR2-agonistic
activities in human blood. This compound is now being evaluated in animal models of
immunization for potential adjuvantic activity.
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Experimental methods for all compounds in Schemes 1–4, and 6–7 are described in
Supporting Information. All of the solvents and reagents used were obtained commercially
and used as such unless noted otherwise. Moisture- or air-sensitive reactions were conducted
under nitrogen atmosphere in oven-dried (120 °C) glass apparatus. Solvents were removed
under reduced pressure using standard rotary evaporators. Flash column chromatography
was carried out using RediSep Rf “Gold” high performance silica columns on CombiFlash
Rf 200 (Teledyne-Isco, Lincoln, NE) instruments unless otherwise mentioned. Thin-layer
chromatography was carried out on silica gel CCM precoated aluminum sheets. Purity for
all final compounds was confirmed to be at least 97% by LC-MS using using two systems:
(a) a 5 µm Zorbax Eclipse Plus 4.6 mm × 150 mm analytical reverse phase C18 column with
H2O-isopropanol (with 0.1% CF3COOH in both mobile phases), and (b) a 4.6 × 150 mm
Hamilton PRP-1 (100 Å pore size) column with H2O-CH3CN gradients (with 0.1%
CF3COOH in both mobile phases). An Agilent ESI-TOF Accurate Mass spectrometer (mass
accuracy of 5 ppm) operating in the positive ion acquisition mode was used. Total ion
current from 150 to 3500 Da was measured.
Synthesis of Compound 40: (2S,2'S)-dimethyl 2,2'-(((2R,2'R)-3,3'-disulfanediylbis(2-((tert-
butoxycarbonyl)amino)propanoyl))bis(azanediyl))bis(3-(tert-butoxy)propanoate)
To a solution of L-cystine (500 mg, 2.08 mmol) in water were added triethylamine (870 µL,
6.24 mmol) and Di-tert-butyl-dicarbonate (1.35 g, 6.24 mmol). The reaction mixture was
stirred at room temperature for 2h. After completion of the reaction, the solvent was
evaporated under reduced pressure. The residue was dissolved in ethyl acetate and washed
with 10% HCl. The organic layer was dried over anhydrous sodium sulfate, filtered and
evaporated under reduced pressure to obtain the crude product which was purified using
column chromatography (15% MeOH/CH2Cl2) to obtain compound Nα,Nα′-di-Boc-L-cystine
(870 mg, 95%). To a solution of Nα,Nα′-di-Boc-L-cystine (500 mg, 1.13 mmol) in anhydrous
DMF were added H-Ser(tBu)-OMe.HCl (576 mg, 2.72 mmol), HOBt (460 mg, 3.4 mmol),
and triethylamine (475 µL, 3.4 mmol). The reaction mixture was stirred at 0 °C for 30 min,
followed by addition of EDCI (652 mg, 3.4 mmol) at 0 °C. The reaction mixture was stirred
at room temperature for 16 h, followed by evaporation of the solvent under reduced
pressure. The residue was then dissolved in ethyl acetate and washed with water. The
organic solvent was dried over anhydrous sodium sulfate, filtered and, evaporated under
reduced pressure to obtain the crude product which was purified using column
chromatography (50% EtOAc/hexanes) to obtain compound 40 (645 mg, 75%). 1H NMR
(500 MHz, CDCl3) δ 7.43 (s, 2H), 5.64 (d, J = 6.52 Hz, 2H), 4.67 (dd, J = 3.80, 7.92 Hz,
4H), 3.76 (dd, J = 3.58, 9.12 Hz, 2H), 3.69 (s, 6H), 3.55 (dd, J = 3.72, 9.16 Hz, 2H), 3.07 (d,
J = 4.12 Hz, 4H), 1.42 (s, 18H), 1.09 (s, 18H). 13C NMR (126 MHz, CDCl3) δ 170.61,
170.34, 155.51, 80.27, 73.60, 61.83, 53.86, 53.21, 52.41, 43.56, 28.45, 27.37. MS (ESI)
calculated for C32H58N4O12S2, m/z 754.34, found 777.36 (M + Na)+.
Synthesis of Compound 41: (S)-methyl 3-(tert-butoxy)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-mercaptopropanamido)propanoate
To a solution of 40 (600 mg, 0.79 mmol) in wet dichloromethane was added
tributylphosphine (198 µL, 0.79 mmol). The reaction mixture was stirred at room
temperature for 30 min. After completion of the reaction, the solvent was removed under
reduced pressure to obtain the crude product which was purified using column
chromatography (50% EtOAc/hexanes) to obtain compound 41 (565 mg, 94%). 1H NMR
(500 MHz, CDCl3) δ 6.93 (d, J = 8.03 Hz, 1H), 5.50 (d, J = 5.76 Hz, 1H), 4.66 (dt, J = 2.59,
5.73 Hz, 1H), 4.38 (s, 1H), 3.82 (dd, J = 2.95, 9.11 Hz, 1H), 3.74 (s, 3H), 3.58 (dd, J = 3.20,
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9.10 Hz, 1H), 3.07 (ddd, J = 4.23, 8.05, 13.78 Hz, 1H), 2.75 (ddd, J = 6.46, 10.12, 13.91 Hz,
1H), 1.78 (t, J = 8.52 Hz, 1H), 1.45 (s, 9H), 1.13 (s, 9H). 13C NMR (126 MHz, CDCl3) δ
170.64, 169.96, 155.32, 80.50, 73.73, 61.64, 55.70, 53.27, 52.62, 28.42, 27.44, 27.42. MS
(ESI) calculated for C16H30N2O6S, m/z 378.18, found 401.18 (M + Na)+.
General Procedure for S-alkylation (Synthesis of Compound 42): (S)-methyl 3-(tert-
butoxy)-2-((R)-2-((tert-butoxycarbonyl)amino)-3-((2-
hydroxyethyl)thio)propanamido)propanoate
To a solution of compound 41 (100 mg, 0.26 mmol) in DMF were added triethylamine (73
µL, 0.52 mmol) and 2-iodoethanol (24 µL, 0.31 mmol). The reaction mixture was stirred at
90 °C for 2h. After completion of the reaction, the solvent was removed under reduced
pressure to obtain the crude product which was purified using column chromatography (70%
EtOAc/hexanes) to obtain compound 42 (84 mg, 77%). 1H NMR (500 MHz, CDCl3) δ
7.31–7.23 (m, 1H), 5.59 (d, J = 6.79 Hz, 1H), 4.68 (dt, J = 3.04, 8.15 Hz, 1H), 4.39 (d, J =
4.71 Hz, 1H), 3.83 (dd, J = 3.00, 9.17 Hz, 1H), 3.80 (t, J = 5.67 Hz, 2H), 3.75 (s, 3H), 3.58
(dd, J = 3.21, 9.17 Hz, 1H), 3.02 (dd, J = 5.47, 13.97 Hz, 1H), 2.89 (dd, J = 7.05, 13.97 Hz,
1H), 2.86–2.74 (m, 3H), 1.46 (s, 9H), 1.15 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 170.72,
170.60, 155.55, 80.40, 73.74, 61.79, 61.42, 53.95, 53.25, 52.58, 35.76, 35.06, 28.40, 27.37.
MS (ESI) calculated for C18H34N2O7S, m/z 422.20, found 445.21 (M + Na)+.
Synthesis of Compound 43: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-
yl)amino)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl palmitate
Compound 42 (50 mg, 0.11 mmol) was palmitoylated using the general procedure for
palmitoylation (see synthesis of compound 28) to obtain compound 43 (70 mg, 90%). 1H
NMR (500 MHz, CDCl3) δ 7.13 (d, J = 7.85 Hz, 1H), 5.44 (s, 1H), 4.64 (dt, J = 3.01, 8.12
Hz, 1H), 4.32 (d, J = 4.42 Hz, 1H), 4.22 (t, J = 6.60 Hz, 2H), 3.81 (dd, J = 2.94, 9.11 Hz,
1H), 3.72 (s, 3H), 3.56 (dd, J = 3.20, 9.12 Hz, 1H), 2.99 (dd, J = 5.57, 13.93 Hz, 1H), 2.90
(dd, J = 6.73, 13.93 Hz, 1H), 2.87–2.76 (m, 2H), 2.30 (t, J = 7.59 Hz, 2H), 1.64–1.56 (m,
2H), 1.44 (s, 9H), 1.32–1.21 (m, 24H), 1.12 (s, 9H), 0.86 (t, J = 6.95 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 173.77, 170.57, 170.49, 155.35, 80.36, 73.63, 63.11, 61.76, 53.81,
53.30, 52.54, 34.94, 34.30, 32.04, 31.13, 29.81, 29.80, 29.77, 29.74, 29.59, 29.48, 29.40,
29.27, 28.41, 27.41, 25.00, 22.81, 14.25. MS (ESI) calculated for C34H64N2O8S, m/z
660.43, found 683.44 (M + Na)+.
Synthesis of Compound 44: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-
yl)amino)-3-oxopropyl)thio)ethyl palmitate, trifluoroacetate
Compound 43 (50 mg, 0.07 mmol) was deprotected with trifluoroacetic acid as described
earlier in the general procedure for one step deprotection of N-Boc and O-tert-Butyl (see
synthesis of compound 11) to obtain compound 44 as trifluoroacetate salt (46 mg,
quantitative yield). 1H NMR (500 MHz, CDCl3) δ 8.48 (d, J = 7.69 Hz, 1H), 4.71–4.64 (m,
1H), 4.34 (t, J = 6.43 Hz, 1H), 4.26–4.18 (m, 2H), 3.96–3.90 (m, 1H), 3.86 (dd, J = 5.34,
11.71 Hz, 1H), 3.76 (s, 3H), 3.16 (dd, J = 5.59, 14.52 Hz, 1H), 3.01 (dd, J = 7.16, 14.54 Hz,
1H), 2.81 (t, J = 6.49 Hz, 2H), 2.31 (t, J = 7.66 Hz, 2H), 1.59 (p, J = 7.43 Hz, 2H), 1.37–
1.12 (m, 26H), 0.88 (t, J = 6.96 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.58, 170.29,
168.27, 62.63, 61.83, 55.40, 52.98, 52.83, 34.32, 33.06, 32.08, 30.90, 29.86, 29.84, 29.82,
29.67, 29.52, 29.45, 29.31, 24.99, 22.84, 14.27. MS (ESI) calculated for C25H48N2O6S, m/z
504.32, found 505.34 (M + H)+.
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Synthesis of Compound 45: (S)-methyl 3-(tert-butoxy)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-((3-hydroxypropyl)thio)propanamido)propanoate
Compound 41 (60 mg, 0.16 mmol) was S-alkylated with 3-iodo-1-propanol (18 µL, 0.19
mmol) as described in the general procedure for S-alkylation (see synthesis of compound 42)
to obtain compound 45 (50 mg, 72%). 1H NMR (500 MHz, CDCl3) δ 7.23 (d, J = 7.64 Hz,
1H), 5.53 (s, 1H), 4.67 (dt, J = 3.01, 8.20 Hz, 1H), 4.34 (d, J = 4.72 Hz, 1H), 3.83 (dd, J =
2.96, 9.14 Hz, 1H), 3.80–3.70 (m, 5H), 3.58 (dd, J = 3.18, 9.14 Hz, 1H), 2.96 (dd, J = 5.42,
14.04 Hz, 1H), 2.87 (dd, J = 7.03, 14.04 Hz, 1H), 2.80 (d, J = 5.68 Hz, 1H), 2.75–2.69 (m,
1H), 2.24 (s, 1H), 1.91–1.82 (m, 2H), 1.46 (s, 9H), 1.15 (s, 9H). 13C NMR (126 MHz,
CDCl3) δ 170.69, 155.50, 80.42, 73.73, 61.82, 60.92, 53.49, 53.25, 52.58, 34.86, 32.04,
28.49, 28.42, 27.40. MS (ESI) calculated for C19H36N2O7S, m/z 436.22, found 459.23 (M +
Na)+.
Synthesis of Compound 46: 3-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-
yl)amino)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)propyl palmitate
Compound 45 (40 mg, 0.09 mmol) was palmitoylated using the general procedure for
palmitoylation (see synthesis of compound 28) to obtain compound 46 (50 mg, 81%). 1H
NMR (500 MHz, CDCl3) δ 7.16 (d, J = 7.75 Hz, 1H), 5.44 (s, 1H), 4.65 (dt, J = 3.02, 8.14
Hz, 1H), 4.29 (d, J = 4.64 Hz, 1H), 4.18–4.09 (m, 2H), 3.81 (dd, J = 2.94, 9.10 Hz, 1H),
3.73 (s, 3H), 3.56 (dd, J = 3.20, 9.10 Hz, 1H), 2.95 (dd, J = 5.46, 13.87 Hz, 1H), 2.85 (dd, J
= 6.94, 13.88 Hz, 1H), 2.64 (td, J = 6.72, 13.14 Hz, 2H), 2.28 (t, J = 7.61 Hz, 2H), 1.98–
1.85 (m, 2H), 1.63–1.54 (m, 2H), 1.44 (s, 9H), 1.30–1.21 (m, 24H), 1.13 (s, 9H), 0.86 (t, J =
6.96 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.95, 170.59, 155.32, 80.33, 73.62, 62.70,
61.78, 53.79, 53.27, 52.53, 34.70, 34.39, 32.04, 29.80, 29.77, 29.73, 29.59, 29.48, 29.40,
29.29, 29.01, 28.73, 28.41, 27.40, 25.06, 22.81, 14.25. MS (ESI) calculated for
C35H66N2O8S, m/z 674.45, found 697.45 (M + Na)+.
Synthesis of Compound 47: 3-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-
yl)amino)-3-oxopropyl)thio)propyl palmitate, trifluoroacetate
Compound 46 (50 mg, 0.07 mmol) was deprotected with trifluoroacetic acid as described
earlier in the general procedure for one step deprotection of N-Boc and O-tert-Butyl (see
synthesis of compound 11) to obtain compound 47 as trifluoroacetate salt (47 mg,
quantitative yield). 1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 6.83 Hz, 1H), 4.66 (s, 1H),
4.15 (t, J = 6.35 Hz, 2H), 4.01–3.87 (m, 3H), 3.79 (s, 3H), 3.05 (dd, J = 3.85, 13.59 Hz, 1H),
2.93–2.85 (m, 1H), 2.62 (t, J = 7.07 Hz, 2H), 2.30 (dd, J = 6.35, 13.88 Hz, 2H), 1.91 (p, J =
6.69 Hz, 2H), 1.59 (dd, J = 7.17, 14.37 Hz, 2H), 1.45–1.09 (m, 26H), 0.88 (t, J = 6.96 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 174.33, 170.57, 62.72, 62.67, 55.17, 53.43, 52.97,
35.43, 34.42, 32.07, 29.85, 29.81, 29.81, 29.78, 29.65, 29.51, 29.44, 29.32, 28.75, 28.57,
25.08, 22.84, 14.28. MS (ESI) calculated for C26H50N2O6S, m/z 518.33, found 541.33 (M +
Na)+.
Synthesis of Compound 48: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-
yl)amino)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)acetic acid
To a solution of compound 41 (100 mg, 0.26 mmol) in DMF were added triethylamine (73
µL, 0.52 mmol) and iodoacetic acid (60 mg, 0.31 mmol). The reaction mixture was stirred at
90 °C for 2h. After completion of the reaction, the solvent was removed under reduced
pressure to obtain the residue. The residue was dissolved in ethyl acetate, followed by
washing with 10% HCl. The organic layer was dried over anhydrous sodium sulfate, filtered
and, evaporated under reduced pressure to obtain the crude product which was purified
using column chromatography (10% MeOH/CH2Cl2) to obtain compound 48 (80 mg,
71%). 1H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 4.79 Hz, 1H), 5.69 (d, J = 5.36 Hz, 1H),
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4.66 (dt, J = 3.11, 7.67 Hz, 1H), 4.43 (d, J = 4.09 Hz, 1H), 3.80 (dd, J = 3.19, 9.23 Hz, 1H),
3.73 (s, 3H), 3.59 (dd, J = 3.20, 9.19 Hz, 1H), 3.44–3.26 (m, 2H), 3.03 (d, J = 4.67 Hz, 2H),
1.44 (s, 9H), 1.13 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 173.53, 170.96, 170.63, 155.70,
80.65, 73.91, 61.73, 53.59, 53.39, 52.63, 35.21, 34.08, 28.39, 27.39, 27.35. MS (ESI)
calculated for C18H32N2O8S, m/z 436.18, found 459.18 (M + Na)+.
Synthesis of Compound 49: (S)-methyl 3-(tert-butoxy)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-((2-(hexadecyloxy)-2-oxoethyl)thio)propanamido)propanoate
To a solution of 48 (60 mg, 0.13 mmol) in anhydrous DMF were added 1-hexadecanol (50
mg, 0.20 mmol), HOBt (35 mg, 0.26 mmol), and triethylamine (36 µL, 0.26 mmol). The
reaction mixture was stirred at 0 °C for 30 min, followed by addition of EDCI (50 mg, 0.26
mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h, followed by
evaporation of the solvent under reduced pressure. The residue was then dissolved in ethyl
acetate and washed with water. The organic solvent was dried over anhydrous sodium
sulfate, filtered and, evaporated under reduced pressure to obtain the crude product which
was purified using column chromatography (25% EtOAc/hexanes) to obtain compound 49
(77 mg, 85%). 1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 7.84 Hz, 1H), 5.55 (d, J = 7.44
Hz, 1H), 4.65 (dt, J = 2.98, 7.95 Hz, 1H), 4.41 (d, J = 6.59 Hz, 1H), 4.12 (t, J = 6.86 Hz,
2H), 3.82 (dd, J = 3.03, 9.05 Hz, 1H), 3.73 (d, J = 3.35 Hz, 3H), 3.57 (dd, J = 3.27, 9.06 Hz,
1H), 3.37 (q, J = 15.34 Hz, 2H), 2.99 (ddd, J = 6.30, 14.18, 33.64 Hz, 2H), 1.67–1.59 (m,
2H), 1.43 (s, 9H), 1.38–1.22 (m, 26H), 1.13 (d, J = 4.63 Hz, 9H), 0.87 (t, J = 6.95 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 170.97, 170.63, 170.46, 155.41, 80.23, 73.61, 66.00,
61.73, 53.39, 53.25, 52.53, 35.86, 34.34, 32.05, 29.82, 29.81, 29.79, 29.78, 29.72, 29.65,
29.50, 29.37, 28.61, 28.41, 27.38, 25.94, 22.83, 14.28. MS (ESI) calculated for
C34H64N2O8S, m/z 660.43, found 683.44 (M + Na)+.
Synthesis of Compound 50: (S)-methyl 2-((R)-2-amino-3-((2-(hexadecyloxy)-2-
oxoethyl)thio)propanamido)-3-hydroxypropanoate, trifluoroacetate
Compound 49 (50 mg, 0.07 mmol) was deprotected with trifluoroacetic acid as described
earlier in the general procedure for one step deprotection of N-Boc and O-tert-Butyl (see
synthesis of compound 11) to obtain compound 50 as trifluoroacetate salt (46 mg,
quantitative yield). 1H NMR (500 MHz, CDCl3) δ 8.74 (d, J = 7.57 Hz, 1H), 4.69–4.63 (m,
1H), 4.38 (t, J = 6.68 Hz, 1H), 4.16–4.05 (m, 2H), 3.88 (dt, J = 7.17, 11.77 Hz, 2H), 3.74 (s,
3H), 3.49–3.39 (m, 3H), 3.24 (dd, J = 4.86, 14.44 Hz, 1H), 3.05 (dd, J = 8.09, 14.60 Hz,
1H), 1.66–1.58 (m, 2H), 1.36–1.18 (m, 27H), 0.87 (t, J = 6.96 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 172.58, 170.30, 168.27, 66.86, 61.72, 55.38, 52.90, 52.86, 50.84, 34.52,
34.34, 32.06, 29.86, 29.84, 29.81, 29.78, 29.69, 29.52, 29.44, 28.48, 25.94, 22.84, 14.28. MS
(ESI) calculated for C25H48N2O6S, m/z 504.32, found 505.34 (M + H)+.
Synthesis of Compound 51: 3-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-
yl)amino)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)propanoic acid
Compound 41 (60 mg, 0.16 mmol) was S-alkylated with 3-iodopropionic acid (38 mg, 0.19
mmol) as described for the synthesis of compound 48 to afford compound 51 (55 mg,
78%). 1H NMR (500 MHz, CDCl3) δ 7.37 (d, J = 7.24 Hz, 1H), 5.54 (d, J = 6.99 Hz, 1H),
4.69 (dt, J = 3.01, 8.19 Hz, 1H), 4.42 (d, J = 6.21 Hz, 1H), 3.83 (dd, J = 2.99, 9.20 Hz, 1H),
3.75 (s, 3H), 3.58 (dd, J = 3.12, 9.19 Hz, 1H), 2.97–2.82 (m, 4H), 2.73–2.61 (m, 2H), 1.46
(s, 9H), 1.15 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 175.80, 170.92, 170.85, 155.56, 80.49,
73.89, 61.87, 53.50, 53.22, 52.68, 34.65, 34.59, 28.40, 27.37, 26.84. MS (ESI) calculated for
C19H34N2O8S, m/z 450.20, found 473.20 (M + Na)+.
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Synthesis of Compound 52: (S)-methyl 3-(tert-butoxy)-2-((R)-2-((tert-
butoxycarbonyl)amino)-3-((3-(hexadecyloxy)-3-oxopropyl)thio)propanamido)propanoate
Compound 51 (45 mg, 0.1 mmol) was esterified with 1-hexadecanol using the procedure as
described for the synthesis of compound 49 to afford compound 52 (51 mg, 76%). 1H NMR
(500 MHz, CDCl3) δ 7.18 (d, J = 7.80 Hz, 1H), 5.48 (d, J = 6.07 Hz, 1H), 4.67 (dt, J = 2.98,
8.15 Hz, 1H), 4.37 (d, J = 5.20 Hz, 1H), 4.08 (t, J = 6.81 Hz, 2H), 3.83 (dd, J = 2.90, 9.10
Hz, 1H), 3.74 (s, 3H), 3.57 (dd, J = 3.19, 9.11 Hz, 1H), 2.98 (dd, J = 5.56, 14.00 Hz, 1H),
2.87 (dt, J = 6.74, 13.37 Hz, 3H), 2.64 (ddd, J = 2.77, 6.13, 10.71 Hz, 2H), 1.69 (s, 1H),
1.65–1.58 (m, 2H), 1.45 (d, J = 12.81 Hz, 9H), 1.35–1.22 (m, 25H), 1.14 (s, 9H), 0.88 (t, J =
6.93 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.15, 170.62, 170.58, 155.37, 80.32, 75.57,
73.64, 68.95, 65.14, 61.81, 53.64, 53.24, 52.57, 52.02, 35.38, 34.81, 34.72, 32.06, 29.84,
29.82, 29.80, 29.74, 29.67, 29.51, 29.41, 28.68, 28.42, 27.41, 27.29, 26.03, 22.84, 14.29. MS
(ESI) calculated for C35H66N2O8S, m/z 674.45, found 697.45 (M + Na)+.
Synthesis of Compound 53: (S)-methyl 2-((R)-2-amino-3-((3-(hexadecyloxy)-3-
oxopropyl)thio)propanamido)-3-hydroxypropanoate, trifluoroacetate
Compound 52 (40 mg, 0.06 mmol) was deprotected with trifluoroacetic acid as described
earlier in the general procedure for one step deprotection of N-Boc and O-tert-Butyl (see
synthesis of compound 11) to obtain compound 53 as trifluoroacetate salt (37 mg,
quantitative yield). 1H NMR (500 MHz, CDCl3) δ 8.53 (d, J = 7.24 Hz, 1H), 4.68 (s, 1H),
4.38 (s, 1H), 4.08 (t, J = 6.77 Hz, 2H), 3.99–3.92 (m, 1H), 3.87 (dd, J = 4.49, 11.04 Hz, 1H),
3.75 (s, 3H), 3.49 (s, 1H), 3.13 (dd, J = 4.87, 14.36 Hz, 1H), 2.97 (dd, J = 7.38, 14.37 Hz,
1H), 2.83 (tq, J = 6.79, 13.35 Hz, 2H), 2.63 (t, J = 6.84 Hz, 2H), 1.60 (dd, J = 6.88, 13.92
Hz, 2H), 1.35–1.20 (m, 27H), 0.88 (t, J = 6.95 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
172.99, 170.32, 65.60, 55.35, 52.92, 52.65, 34.25, 32.07, 29.86, 29.84, 29.82, 29.78, 29.71,
29.52, 29.46, 28.61, 26.50, 26.03, 22.85, 14.29. MS (ESI) calculated for C26H50N2O6S, m/z
518.33, found 519.35 (M + H)+.
TLR2-specific NF-κB induction
The induction of NF-κB in a TLR2-specific reporter gene assay was quantified using HEK-
Blue™ cells as previously described by us.14 HEK293 cells stably transfected with human
TLR2 and alkaline phosphatase (sAP) were obtained from InvivoGen (San Diego, CA), and
were maintained in HEK-Blue™ Selection medium containing zeocin and normocin. Stable
expression of secreted alkaline phosphatase (sAP) under control of NF-κB promoters is
inducible by TLR2 agonists, and extracellular sAP in the supernatant is proportional to NF-
κB induction. HEK-Blue cells were incubated at a density of ~105 cells/mL in a volume of
80 µL/well, in 384-well, flat-bottomed, cell culture-treated microtiter plates until confluency
was achieved, and then stimulated with serially-diluted aliquots of compounds for 12 h. sAP
was assayed spectrophotometrically using an alkaline phosphatase-specific chromogen
(present in the HEK-detection medium as supplied by the vendor) at 620 nm.
Experiments involving human blood
Human blood was obtained from healthy adults by antecubital venipuncture in accordance
with University of Kansas Human Subjects Experimentation protocols (Protocol # HSCL
12397).
Phosflow™ flow cytometric assay for p38MAPK
Assays were performed as described by us previously.15;17;37 Briefly, 1 mL aliquots of fresh
whole blood, anticoagulated with heparin were incubated with 25 µL an equal volume of
graded concentrations of compounds diluted in saline for 15 min at 37°C. Erythrocytes were
lysed and leukocytes were fixed in one step by mixing 200 µL of the samples in 4 mL pre-
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warmed Whole Blood Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA). After
washing the cells at 500 g for 8 min in buffer, the cells were permeabilized in ice-cold
methanol for 30 min, washed twice in phosphate-buffered saline and transferred to a
Millipore MultiScreen BV 1.2µ filter plate and stained with phycoerythrin (PE)-conjugated
mouse anti-p38MAPK (Becton-Dickinson Biosciences; mAb recognizes the conserved dual-
phosphorylated pT180/pY182 site of p38α, β, γ, and δ isoforms of p38MAPK) The cells
were washed twice in the plate by aspiration as per protocols supplied by the vendor.
Cytometry was performed using a BD FACSArray instrument in the single-color mode for
PE acquisition on 20,000 gated events. Post-acquisition analyses were performed using
FlowJo v 7.0 software (Treestar, Ashland, OR).
CD11b flow cytometric assay
Assays were performed as described by us previously.15;17;37 Briefly, 1 mL aliquots of fresh
anticoagulated whole blood were incubated with 25 µL of graded dilutions of the
compounds for 1 hour at 37° C. Negative (saline) controls were included in each
experiment. Samples were placed on ice for 15 min before 20 µL of anti-CD11b/Mac-1
antibody (Becton-Dickinson) were added to each sample tube and allowed to incubate on ice
for 30 min. This 0° C incubation step prevented internalization of antibody, and ensured
staining of only extracellularly expressed CD11b. Erythrocytes were lysed and leukocytes
were fixed in one step by mixing 200 µL of the samples in 4 mL pre-warmed Whole Blood
Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA). After washing the cells
twice at 200 g for 5 min in CBA buffer, the cells were transferred to a 96-well plate. Flow
cytometry was performed using a BD FACSArray instrument in the single-color mode for
PE acquisition on 20,000 gated events. Post-acquisition analyses were performed using
FlowJo v 7.0 software.
Animal experiments
All experiments were performed in accordance with animal care protocols approved by the
University of Kansas IACUC Committee. Cohorts of 5 outbred CF-1 mice per group were
immunized on Day 0 with vehicle (control 1), 10 µg/animal of bovine α-lactalbumin alone
(control 2), or 10 µg/animal α-lactalbumin mixed with 50 µg/animal of either GLA24;25
(TLR4 agonist), PAM2CS14 (TLR2 agonist), or imidazoquinoline (compound 1 in Ref. 12;
TLR7/8 agonist). All antigen/adjuvant preparations were in sterile, physiological saline
(vehicle). A volume of 0.2 mL was injected intramuscularly into the flank region. Animals
were boosted once on Day 14, and were bled by terminal cardiac puncture (under isoflurane
anesthesia) on Day 21. Sera were stored at −80° C until assayed.
Enzyme-linked immunosorbent assays (ELISA)
A description of the semi-automated 384-well ELISA procedures has been published
previously.12 A Precision 2000 liquid handler (Bio-Tek, Winooski, VT) was used for all
serial dilution and reagent addition steps, and a Bio-Tek ELx405 384-well plate washer was
employed for plate washes; 100 mM phosphate-buffered saline (PBS) pH 7.4, containing
0.1% Tween-20 was used as wash buffer. Nunc-Immuno MaxiSorp (384-well) plates were
coated with α-lactalbumin (10 µg/mL, in a volume of 80 µL/well) in 100 mM carbonate
buffer, pH 9.0 overnight at 4° C. After 3 washes, the plates were blocked with 3% bovine
serum albumin (in PBS, pH 7.4) for 1 h at room temperature. Serum samples (in
quadruplicate) were serially diluted in a separate 384-well plate using the liquid handler.
After three additional washes of the assay plate, 30 µL of the serum dilutions were
transferred from the dilution plate using the liquid handler, and the assay plate incubated at
37°C for 2 h. The assay plate was washed three times, and 30 µl of 1:10,000 diluted
appropriate anti-mouse immunoglobulin isotypes (IgG1, IgG2a) conjugated with horseradish
peroxidase was added to all wells. Following an incubation step at 37°C for 1 h, and three
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washes, tetramethylbenzidine substrate was added at concentrations recommended by
vendor (Sigma, St. Louis, MO). The chromogenic reaction was terminated at 30 min by the
addition of 2M H2SO4. Plates were then read at 450 nm using a SpectraMax M4 device
(Molecular Devices, Sunnyvale, CA). Data visualization and statistics (Student’s T test for
significance) were performed using Origin 7.0 (Northampton, MA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Abbreviations




EC50 Half-maximal effective concentration
EDCI 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
ESI-TOF Electrospray ionization-time of flight
Fmoc-Osu 9-Fluorenylmethyl N-succinimidyl carbonate
HEK Human embryonic kidney
HOBt 1-Hydroxybenzotriazole
IMDQ Imidazoquinoline
IgG1 Immunoglobulin G subclass 1
IgG2a Immunoglobulin G subclass 2a
NF-κB Nuclear factor-κB
p38MAPK p38 Mitogen activated protein kinase
PBMCs Peripheral blood mononuclear cells
PE Phycoerythrin
PAM Palmitoyl
sAP Secreted alkaline phosphatase
SAR Structure activity relationship
Ser Serine
Th1 Helper T lymphocyte, type 1
Th2 Helper T lymphocyte, type 2
TLR Toll like receptor
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IgG1 (Th2) and IgG2a(Th1) immunoglobulin isotype titers in outbred CF-1 mice immunized
with unadjuvanted α-lactalbumin, or α-lactalbumin adjuvanted with GLA, PAM2CS, or
imidazoquinoline. α-lactalbumin-specific immunoglobulin levels were quantified by
standard antibody-capture ELISA, performed in liquid handler-assisted 384-well format.
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TLR2-specific NF-κB induction by selected analogues. Means and standard deviations of
quadruplicate samples are shown.
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CD11b (Top) and p38MAPK upregulation in human granulocytes. Whole human blood was
stimulated ex vivo with lipopeptides, and assayed by flow cytometry. Representative
experiment of three independent experiments are shown.
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The crystal structure of PAM2CSK4 bound to TLR2/TLR6 heterodimer, showing crucial H-
bond interactions of the lipopeptide with the receptor. The lipopeptide is depticted in ball-
and-stick model. Adapted from Ref. 39; PDB code: 3A79.
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